Matrix Laboratories is in the process of consolidation and revisiting its strategy. The company has positioned itself in the global road map by integrating capabilities, according to company's sources. The company's strategic vision is expected to remain unchanged and the transaction creates further growth opportunities for Matrix and its employees and will allow it accelerate its existing expansion plans in India and abroad.
The global pharmaceutical industry is consolidating faster than ever before. This growing consolidation is a bid to share resources and capabilities to shrink time-to-market and grab a larger share of the market.
Matrix has been producing active pharmaceutical ingredients for wide therapeutic categories including ARVs, anti-bacterials, CNS, anti-asthma, anti-virals, pain management, anti hyperlipidimic agents. During 2005-06, the company spent 5.88 per cent on R&D as a percentage of its turnover. The company's cumulative US DMF filings by 2005-06 stood at 88, while the cumulative patents filed were 54. The company is aiming at filing 30 ANDAs and DMFs each in 2006-07.
Matrix has recently signed a Licensing Agreement with Gilead for manufacture and sale of a generic version of Tenofovir Disoproxil Fumarate using Gilead's proprietary technology. The company will have access to Gilead's technology for manufacture and sale of Tenofovir in 95 countries including India. It will also have the right to develop combination therapies using Tenofovir to enhance the effectiveness of existing therapies. This license will boost the company's portfolio of anti-retroviral APIs developed for combating HIV/AIDS.